Teva: 'Too early' to say whether merger triggers job cuts

Teva Pharmaceutical Industries ($TEVA) says recent reports of up to 1,500 job cuts from the integration of its recent acquisition, Cephalon, "came from unsubstantiated sources." A U.S. spokeswoman told the Daily Local it's too early to know how the merger will affect Teva and Cephalon employees. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.